Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01701349
Other study ID # OX4317s
Secondary ID
Status Withdrawn
Phase Phase 3
First received October 2, 2012
Last updated April 30, 2014
Start date March 2015
Est. completion date December 2017

Study information

Verified date April 2014
Source OXiGENE
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.


Description:

The Treatment Plan followed for all subjects will consist of:

- A Screening Visit within 14 days before study drug (fosbretabulin or placebo) administration

- A Treatment Phase of 21-day combination treatment (study drug plus chemotherapy) cycles (up to 6 cycles)

- An End of Treatment Phase assessment

- An End of Study Visit occurring 30 days after the last day of study drug administration, as able

After the last clinic visit, all subjects will be followed for survival by monthly phone calls, email, or in-person.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Unresectable, residual, recurrent or persistent ATC, histologically or cytologically confirmed

- Prior cytotoxic therapeutic regimen as primary therapy for curative intent or prior targeted therapies (TKIs) are eligible (Prior taxane or platinum therapy is allowed)

- Untreated ATC following biopsy, surgery for curative intent, palliation, or after radiation therapy has been considered or administered with or without radiosensitizing chemotherapy

- Disease present on clinical exam (measurable or non-measurable)

- Distant metastases (Stage IVC) only must have histologic confirmation of ATC either from the original primary lesion or a metastatic site

- Neoadjuvant therapy with radiation and either radiosensitizing chemotherapy followed by surgery for curative intent, palliation, or biopsy are eligible if residual or persistent ATC is present

- Subjects with tracheostomy are eligible

- ECOG PS 2 or less

- Adequate bone marrow, renal, and hepatic function, electrolytes WNL for the institution

Exclusion Criteria:

- Disease that is able to be completely resected with negative microscopic margins and without any residual disease in the body

- Active brain metastases, including symptomatic involvement, evidence of cerebral edema by prior CT or MRI, radiographic evidence of brain metastasis since definitive therapy, or continued requirement for corticosteroids for cerebral edema

- History of malignancies other than ACT except prior lower grade thyroid malignancy, curatively treated basal cell carcinoma and in-situ melanoma of the skin, cervical intra-epithelial neoplasia,localized prostate cancer, in-situ carcinoma of the breast

- Known intolerance or hypersensitivity to fosbretabulin, paclitaxel, carboplatin or any of their components

- Receiving concurrent investigational therapy or have received investigational therapy for any indication within 28 days of the first scheduled day of dosing

- Grade 3 or greater peripheral neuropathy

- History of prior cerebrovascular event,including transient ischemic attack within the past 6 months

- Uncontrolled hypertension defined as blood pressure >150/100 mm Hg despite medication

- Symptomatic vascular disease (e.g. intermittent claudication)

- History of unstable angina pectoris pattern, myocardial infarction (including non-Q wave) within the past 6 months, or NYHA Class III or IV congestive heart failure

- History of torsade de pointes, ventricular tachycardia, ventricular fibrillation or congenital long QT syndrome.

- Pathologic bradycardia (<60 b/m or heart block(excluding 1st degree block, consisting of PR interval prolongation only)

- ECG findings of clinically significant ventricular arrhythmia, new ST segment elevation or depression, or new Q wave on ECG (PVCs are not excluded).

- QTc interval 480 ms or more

- Requirement of concurrent treatment with any drugs know to prolong the QTc interval, including anti-arrhythmic medications

- Potassium and/or magnesium concentrations below normal range for the reference laboratory

- History of solid organ or bone marrow transplant

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Fosbretabulin + paclitaxel + carboplatin
Fosbretabulin 200 mg/m2 IV infusion
Placebo + paclitaxel + carboplatin
Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
OXiGENE

Outcome

Type Measure Description Time frame Safety issue
Other Determine the proportion of subjects with measurable disease who have objective tumor response, by treatment Maximun length of study for each subject is 2 years from date of randomization No
Primary Overall survival Maximun length of study for each subject is 2 years from date of randomization No
Secondary Number of adverse events of the combination of fosbretabulin + paclitaxel + carboplatin Maximun length of study for each subject is 2 years from date of randomization Yes
Secondary Number of participants with 1-year survival Maximun length of study for each subject is 2 years from date of randomization No
See also
  Status Clinical Trial Phase
Recruiting NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Phase 1
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Terminated NCT00603941 - A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel Phase 1/Phase 2
Completed NCT00280852 - Review of Multimodality Management of Anaplastic Thyroid Cancer N/A
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06079333 - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) Phase 2